15 October 2021 (Friday) - ASH Update

The nice people at the American Society of Hematology sent a little update on recent developments in the treatment of myeloma. Perhaps a tad too clinical for what I need, but all useful reading…

Here are the highlights in multiple myeloma:

Evaluating Venetoclax Plus Daratumumab and Dexamethasone in Relapsed/Refractory MM
Treatment with venetoclax induced deep and durable responses, especially in patients with t(11;14) translocation, according to recent findings published in the Journal of Clinical Oncology.
Daratumumab and Hyaluronidase-fihj Combination Approved for Relapsed/Refractory MM
This indication of daratumumab and hyaluronidase-fihj, in combination with pomalidomide and dexamethasone, includes patients whose disease is refractory to lenalidomide.
ALLO-605 Receives FDA Fast Track Designation for Relapsed/Refractory MM
The phase I IGNITE study evaluating the safety, feasibility, and recommended phase II dose of ALLO-605 began enrolling patients with relapsed or refractory multiple myeloma, or other BCMA-positive malignancies, last year.


No comments:

Post a Comment